Your LDL Is Normal. But Could Your Heart Still Be at Risk?
The lab portal pings. You open the PDF, scan for the one number you know — LDL cholesterol — and there it is, in the normal range. You close the tab feeling vaguely virtuous.
Sound familiar? For many Canadians, that LDL number is the whole story of their heart risk. Cardiologists treat it as the first chapter, not the book. Two tests that never appear on a standard panel — ApoB and Lp(a) — can tell a different story underneath a "fine" LDL.
LDL-C Weighs the Cargo. It Does Not Count the Trucks
A standard panel reports LDL-C: an estimate of how much cholesterol is riding inside your LDL particles. It is a weight, not a head count.
Picture each particle as a tiny delivery truck. Some are packed full; some are half empty. Two people can carry the same cholesterol weight — the same LDL-C — with completely different numbers of trucks on the road. And it is the trucks that slip into artery walls and start plaque.
ApoB: One Tag Per Particle
Every artery-clogging particle in your blood — LDL, VLDL, IDL, remnant particles, even Lp(a) — carries exactly one molecule of apolipoprotein B. One particle, one ApoB.
So an ApoB test does something elegantly simple: it counts how many atherogenic particles are actually circulating, instead of estimating the weight of their cargo.
When the Two Numbers Disagree
Usually, LDL-C and ApoB rise and fall together. The interesting cases are when they disagree — discordance.
Discordance is common in exactly the people who can least afford a missed signal: those with type 2 diabetes, metabolic syndrome, insulin resistance or high triglycerides. Their particles tend to come out smaller and cholesterol-depleted — more trucks, each carrying less. LDL-C reads normal while ApoB is quietly high.
The 2021 Canadian Cardiovascular Society (CCS) guidelines say that when triglycerides are above 1.5 mmol/L, clinicians should use non-HDL cholesterol or ApoB instead of LDL-C — because even a modest triglyceride rise makes LDL-C understate the particle burden, and people get undertreated.
For people on a maximally tolerated statin, CCS uses an ApoB of 0.8 g/L or higher (alongside LDL-C of 2.0 mmol/L or more) as a threshold to discuss add-on therapy such as ezetimibe. European guidelines set ApoB goals by risk level, down to below 0.65 g/L for the very highest-risk patients.
Lp(a): The Risk You Inherit, Not the One You Earn
Lp(a) — say it "L-P-little-a" — is a different animal. It is an LDL-like particle with an extra protein, apolipoprotein(a), attached. Its level is overwhelmingly written in your genes: more than 90% genetically determined, set early in life, and essentially stable from then on.
Diet does not move it. Exercise does not move it. Statins do not meaningfully lower it. Nor can it be guessed from the rest of your panel — the CCS notes it cannot be deduced from other lipid markers or from ApoB.
Which is why both the CCS and the European Atherosclerosis Society (EAS) say the same striking thing: measure Lp(a) once in a person's lifetime, as part of initial lipid screening. One test, once, because the answer barely changes.
About one in five people worldwide carries an elevated level. The CCS treats an Lp(a) of 50 mg/dL or more (paired with 100 nmol/L in CCS documents, 125 nmol/L by the EAS — the units do not convert exactly) as a signal for earlier, more intensive management of other risk factors. The EAS calls 30 to 50 mg/dL a grey zone; above 50 mg/dL, Lp(a) is a risk factor in its own right.
The Honest Part
Two cautions keep this in proportion. First, these are risk markers, not diagnoses. A high ApoB or Lp(a) does not mean you have heart disease; it means the odds deserve a harder look, alongside blood pressure, blood sugar and family history.
Second, for Lp(a), genetic studies strongly support a causal role — people born with variants that raise Lp(a) have higher risk. But no Lp(a)-specific drug has yet proven, in a completed outcomes trial, that lowering it prevents heart attacks; those trials are still running. So today, a high result changes how aggressively clinicians treat everything else, rather than Lp(a) itself. A high Lp(a) is nobody's fault: inheritance, not behaviour.
Neither test is automatically ordered or covered the same way everywhere in Canada — raise both with your clinician rather than assuming they were included.
What to Ask at Your Next Appointment
- Ask for the particle count. With diabetes, metabolic syndrome or high triglycerides, ask whether ApoB adds anything beyond LDL-C.
- Ask for the once-in-a-lifetime test. Never had Lp(a) measured — especially with a family history of early heart disease? Ask for it once.
- Ask what the result changes. A number matters only if it changes a decision: treatment intensity, targets, or check-up frequency.
The Twikup Take
Your panel weighs the cargo and calls it a day. ApoB counts the trucks; Lp(a) reveals the risk you inherited before you made a single lifestyle choice. A "normal" LDL is a good start — it was never the whole story.
Health note: This is general information about lipid testing, not medical advice. ApoB and Lp(a) results need interpretation alongside your full risk profile — discuss testing and treatment decisions with your own clinician.
Image: AI-generated illustration.